The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.

Yoshimi OuchiKatsuhiko NakatsukasaKoichi SakaguchiMidori MoritaHiroshi KoyamaTakayuki MatsudaMakoto KatoEiichi KonishiHisako OnoTetsuya Taguchi

Published in: Journal of bone and mineral metabolism (2020)

Twice-yearly administration of denosumab to the breast cancer patients treated with adjuvant AI, regardless of the skeletal site, resulted in consistent increases in BMD without severe adverse events at 36 months.

Keyphrases

early stage
bone mineral density
giant cell
artificial intelligence
early onset
deep learning
breast cancer risk